- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 13.11. | Vor Biopharma: Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 240 | GlobeNewswire (Europe) | Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected... ► Artikel lesen | |
| 12.11. | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11. | Vor Biopharma Stock Sinks 48% | 8 | RTTNews | ||
| 11.11. | Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial | 12 | Benzinga.com | ||
| 11.11. | Vor Biopharma slumps 26%, prices $100M equity at $10 per share | 1 | Seeking Alpha | ||
| 11.11. | Vor Biopharma Prices Public Offering Of 10 Mln Shares At $10.00/shr | 3 | RTTNews | ||
| 11.11. | Vor Bio prices $100 million public offering of common stock | 5 | Investing.com | ||
| 11.11. | Vor Biopharma: Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock | 143 | GlobeNewswire (Europe) | BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the... ► Artikel lesen | |
| 10.11. | Vor Bio launches $100 million common stock offering | 1 | Investing.com | ||
| 10.11. | Vor Bio launches $100M public stock offering | 2 | Seeking Alpha | ||
| 08.11. | Vor Bio's IgA nephropathy drug shows 55% reduction in proteinuria | 2 | Investing.com | ||
| 08.11. | Vor Bio: Medikament gegen IgA-Nephropathie reduziert Proteinurie um 55 % | 10 | Investing.com Deutsch | ||
| 08.11. | Vor Biopharma: Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China | 106 | GlobeNewswire (Europe) | Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated... ► Artikel lesen | |
| 03.11. | Vor Biopharma Appoints Jeremy Sokolove As New Chief Medical Officer | 3 | RTTNews | ||
| 03.11. | Vor Bio appoints Jeremy Sokolove as chief medical officer | 2 | Investing.com | ||
| 31.10. | Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 29.10. | Vor Biopharma: Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data | 141 | GlobeNewswire (Europe) | Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved =2-point Myasthenia Gravis Activities... ► Artikel lesen | |
| 28.10. | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.10. | Vor Biopharma: Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease | 2 | GlobeNewswire (USA) | ||
| 17.10. | Vor Biopharma: Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025 | 171 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data... ► Artikel lesen |
1 2 3 4 5 Weiter >>
93 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 2,119 | +1,05 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,012 | -10,79 % | SOL Global Investments Corp.: SOL Global Announces Change of Auditor | Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") today announce that it has changed its auditor... ► Artikel lesen | |
| TRINITY BIOTECH | 0,889 | +6,54 % | Trinity Biotech plc: Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation | DUBLIN, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,884 | -0,70 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates | Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 6,240 | +5,76 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,020 | -5,56 % | Ovid Therapeutics Inc.: Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results | Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT)... ► Artikel lesen | |
| EQUILLIUM | 0,830 | -1,43 % | Equillium, Inc.: Equillium Announces Leadership and Corporate Updates | LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics... ► Artikel lesen | |
| GENERATION BIO | 5,030 | +0,40 % | Generation Bio Co.: Generation Bio Announces CEO Transition | • Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE,... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 10,825 | +4,89 % | 4D Molecular Therapeutics, Inc.: 4DMT Appoints Kristian Humer as Chief Financial Officer | EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 12,510 | -0,87 % | Regencell Bioscience Holdings Limited Announces Forward Stock Split | HONG KONG, June 2, 2025 - Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the "Company"), today announced that its board of directors approved a 38-for-one forward stock split to be paid in the... ► Artikel lesen | |
| CABALETTA BIO | 2,090 | -3,24 % | Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update | Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient... ► Artikel lesen | |
| LONGEVERON | 0,601 | -0,45 % | Longeveron stellt Daten zur Alzheimer-Therapie auf der CTAD 2025 vor | ||
| PROKIDNEY | 2,195 | +5,28 % | ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates | Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of... ► Artikel lesen | |
| ATHIRA PHARMA | 4,600 | +1,32 % | Athira Pharma, Inc.: Athira Pharma Announces Reverse Stock Split | BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. ("Athira" or "Company") (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore... ► Artikel lesen | |
| BOLT PROJECTS | 1,610 | +7,33 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +9,69 % bei einem Aktienkurs von 7,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.